Your browser is no longer supported. Please, upgrade your browser.
Settings
PTCT PTC Therapeutics, Inc. daily Stock Chart
PTCT [NASD]
PTC Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.06 Insider Own0.10% Shs Outstand57.93M Perf Week-4.20%
Market Cap2.61B Forward P/E- EPS next Y-1.31 Insider Trans-80.62% Shs Float57.03M Perf Month2.57%
Income-213.20M PEG- EPS next Q-0.78 Inst Own99.10% Short Float7.03% Perf Quarter15.90%
Sales279.00M P/S9.37 EPS this Y-36.40% Inst Trans-2.38% Short Ratio6.47 Perf Half Y52.02%
Book/sh8.74 P/B5.16 EPS next Y56.00% ROA-18.10% Target Price51.75 Perf Year3.89%
Cash/sh6.27 P/C7.19 EPS next 5Y-9.51% ROE-49.10% 52W Range27.53 - 48.99 Perf YTD31.47%
Dividend- P/FCF- EPS past 5Y11.90% ROI-23.00% 52W High-7.90% Beta1.73
Dividend %- Quick Ratio2.60 Sales past 5Y50.10% Gross Margin95.50% 52W Low63.89% ATR1.83
Employees517 Current Ratio2.70 Sales Q/Q24.50% Oper. Margin-72.10% RSI (14)50.04 Volatility3.71% 4.31%
OptionableYes Debt/Eq0.32 EPS Q/Q-262.20% Profit Margin-76.40% Rel Volume0.56 Prev Close44.34
ShortableYes LT Debt/Eq0.28 EarningsAug 06 AMC Payout- Avg Volume619.36K Price45.12
Recom1.90 SMA20-1.10% SMA502.68% SMA20020.45% Volume345,702 Change1.76%
May-13-19Upgrade BofA/Merrill Neutral → Buy $43 → $49
Apr-11-19Initiated Bernstein Outperform $48
Oct-03-18Upgrade BofA/Merrill Underperform → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $66
Jul-19-18Initiated Credit Suisse Outperform $49
Jun-18-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-04-18Downgrade Barclays Equal Weight → Underweight $24 → $26
Jan-29-18Resumed RBC Capital Mkts Sector Perform
Nov-16-17Upgrade JP Morgan Underweight → Neutral
Oct-26-17Downgrade BofA/Merrill Neutral → Underperform
Oct-09-17Downgrade JP Morgan Neutral → Underweight
Sep-29-17Reiterated RBC Capital Mkts Sector Perform
Sep-29-17Reiterated Barclays Equal Weight $22 → $15
Aug-23-17Initiated William Blair Mkt Perform
Mar-16-17Reiterated RBC Capital Mkts Sector Perform $13 → $10
Mar-03-17Downgrade Barclays Overweight → Equal Weight $20 → $13
Nov-14-16Upgrade Credit Suisse Neutral → Outperform
Nov-11-16Upgrade Citigroup Neutral → Buy
Nov-11-16Reiterated RBC Capital Mkts Sector Perform $5 → $13
Jul-26-16Reiterated Wedbush Neutral $12 → $10
Aug-09-19 01:35PM  Edited Transcript of PTCT earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-07-19 02:24AM  PTC Therapeutics (PTCT) Q2 2019 Earnings Call Transcript Motley Fool
Aug-06-19 06:25PM  PTC Therapeutics (PTCT) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM  PTC Therapeutics Reports Second Quarter 2019 Financial Results and Provides a Corporate Update PR Newswire
Aug-05-19 08:00AM  PTC Therapeutics Expands Presence in New Jersey by Securing State-of-the-Art Biologics Facility PR Newswire
Jul-31-19 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jul-30-19 10:38AM  PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Zacks
Jul-23-19 08:00AM  PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2019 Financial Results PR Newswire
Jul-19-19 08:09AM  Should You Worry About PTC Therapeutics, Inc.'s (NASDAQ:PTCT) CEO Pay Cheque? Simply Wall St.
Jul-10-19 05:41PM  5 Health Care Stocks in Gurus' Portfolios GuruFocus.com
Jul-01-19 09:21AM  Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study Zacks
08:00AM  PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics PR Newswire
Jun-28-19 06:40AM  PTC Provides Update on Translarna (ataluren) Application for Label Expansion PR Newswire
Jun-14-19 01:49PM  Did You Miss Therapeutics's (NASDAQ:PTCT) Whopping 511% Share Price Gain? Simply Wall St.
Jun-13-19 09:44AM  Hedge Funds Have Never Been This Bullish On PTC Therapeutics, Inc. (PTCT) Insider Monkey
Jun-07-19 03:02PM  PTC Therapeutics Shares Spike After FDA Approves Drug For Younger Patients Benzinga
01:31PM  PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age PR Newswire
Jun-03-19 08:00AM  PTC Therapeutics Promotes Emily Hill to Chief Financial Officer PR Newswire
May-31-19 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
May-30-19 08:00AM  PTC Therapeutics to Participate at Upcoming Investor Conference PR Newswire
May-20-19 08:00AM  PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders PR Newswire
May-09-19 04:05PM  PTC Therapeutics and MRI Interventions Announce Strategic Investment PR Newswire
May-08-19 04:12PM  Edited Transcript of PTCT earnings conference call or presentation 2-May-19 8:30pm GMT Thomson Reuters StreetEvents +7.89%
08:00AM  PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire
May-07-19 04:33PM  This Biotech Has A 'Swing Factor' In SMA Drugs And It's Slugging Biogen Investor's Business Daily
01:00AM  Data from Pivotal FIREFISH and SUNFISH Studies Demonstrate Clinical Benefit of Risdiplam in Type 1, 2, & 3 Spinal Muscular Atrophy Patients PR Newswire
May-03-19 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
May-02-19 07:15PM  PTC Therapeutics (PTCT) Reports Q1 Loss, Lags Revenue Estimates Zacks
06:07PM  PTC Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  PTC Therapeutics Reports First Quarter 2019 Financial Results and Provides a Corporate Update PR Newswire
May-01-19 12:48PM  Here is What Hedge Funds Think About PTC Therapeutics, Inc. (PTCT) Insider Monkey
Apr-29-19 09:18AM  Translarna (ataluren) is the First Therapy Approved in Brazil for Duchenne Muscular Dystrophy PR Newswire
Apr-25-19 10:33AM  Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-18-19 08:00AM  PTC Therapeutics to Host Conference Call to Discuss First Quarter 2019 Financial Results PR Newswire
Apr-12-19 08:28AM  Have Insiders Been Selling PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares? Simply Wall St.
Apr-01-19 08:00AM  Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders CNW Group
Mar-16-19 08:06AM  Edited Transcript of PTCT earnings conference call or presentation 28-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-15-19 03:43PM  Is PTC Therapeutics, Inc.s (NASDAQ:PTCT) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Mar-06-19 07:55AM  Research Report Identifies E*TRADE Financial, Kennedy-Wilson, Alteryx, PTC Therapeutics, Ocean Power Technologies, and NuVasive with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-04-19 04:30PM  PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire
08:00AM  PTC to Expand Product Portfolio in Latin America with WAYLIVRA PR Newswire
Mar-01-19 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
02:29AM  PTC Therapeutics Inc (PTCT) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-28-19 04:01PM  PTC Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides a Corporate Update PR Newswire
Feb-25-19 04:30PM  PTC Therapeutics Announces Partial Exercise of Underwriter's Option to Purchase Additional Shares PR Newswire
03:12PM  Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal Benzinga
Feb-21-19 10:31AM  Earnings Preview: PTC Therapeutics (PTCT) Q4 Earnings Expected to Decline Zacks
Feb-14-19 08:00AM  PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2018 Financial Results PR Newswire
Feb-13-19 08:00AM  PTC Therapeutics Launches Fifth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy PR Newswire
Feb-01-19 05:53PM  Top Insider Buys Highlight for the Week of Feb. 1 GuruFocus.com
Jan-31-19 08:00AM  PTC Therapeutics Launches New Program to Support Research Projects in Rare, Genetic Disorders PR Newswire
Jan-29-19 10:35AM  What Kind Of Shareholders Own PTC Therapeutics, Inc. (NASDAQ:PTCT)? Simply Wall St.
Jan-28-19 07:45AM  Report: Exploring Fundamental Drivers Behind Realty Income, United Therapeutics, NxStage Medical, PTC Therapeutics, AVEO Pharmaceuticals, and Owens & Minor New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-25-19 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jan-23-19 04:33PM  Why Capital One Financial, PTC Therapeutics, and Quotient Technology Slumped Today Motley Fool -10.24%
03:08PM  Here's Why PTC Therapeutics Fell as Much as 11.7% Today Motley Fool
08:55AM  PTC Therapeutics Announces Pricing of Public Offering of Common Stock PR Newswire
07:22AM  The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study Benzinga
Jan-22-19 04:08PM  PTC Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
Jan-07-19 08:10AM  PTC Therapeutics Announces Executive Team Updates Focused on Accelerating Pipeline and Bringing Gene Therapy Manufacturing In-house PR Newswire
08:00AM  PTC Therapeutics Provides Corporate Update and Outlines 5-year Strategic Plan at 2019 J.P. Morgan Healthcare Conference PR Newswire
Jan-03-19 09:56AM  Praesidium Investment Managements Return, AUM, and Holdings Insider Monkey
Jan-02-19 04:30PM  PTC Therapeutics to Participate at Upcoming Investor Conference PR Newswire
Dec-20-18 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Dec-18-18 08:30AM  PTC Therapeutics Deepens Financial and Commercial Expertise of Board with Two New Appointments PR Newswire
Dec-17-18 05:29PM  Roche's SMA Candidate Risdiplam Gets PRIME Designation in EU Zacks
07:14AM  Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)? Zacks
Dec-13-18 02:44PM  Is PTC Therapeutics, Inc.s (NASDAQ:PTCT) CEO Paid Enough Relative To Peers? Simply Wall St.
08:32AM  Ghost Tree Capitals AUM, Returns and Holdings Insider Monkey
Dec-11-18 01:04AM  Hedge Funds Are Buying PTC Therapeutics, Inc. (PTCT) Insider Monkey
Dec-07-18 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire -7.05%
Nov-30-18 07:50AM  Report: Exploring Fundamental Drivers Behind J.B. Hunt Transport Services, Kura Oncology, National Beverage, Benefitfocus, PTC Therapeutics, and Walgreens Boots Alliance New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-21-18 11:52AM  Edited Transcript of PTCT earnings conference call or presentation 5-Nov-18 9:30pm GMT Thomson Reuters StreetEvents +5.36%
Nov-16-18 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Nov-09-18 08:03AM  New Strong Sell Stocks for November 9th Zacks -7.00%
Nov-07-18 09:30PM  Here's Why PTC Therapeutics Dropped 18% in October Motley Fool +5.09%
Nov-06-18 07:30AM  PTC Therapeutics (PTCT) Reports Q3 Loss, Lags Revenue Estimates Zacks -8.28%
05:01AM  PTC Therapeutics: 3Q Earnings Snapshot Associated Press
12:30AM  Amazon, Pandora, PTC Therapeutics, and More: Why These Stocks Are Trending Insider Monkey
Nov-05-18 04:01PM  PTC Therapeutics Reports Third Quarter 2018 Financial Results and Provides a Corporate Update PR Newswire
Oct-30-18 08:00AM  PTC Therapeutics to Participate at Upcoming Investor Conference PR Newswire
Oct-29-18 10:31AM  PTC Therapeutics (PTCT) Q3 Earnings Preview: What to Watch Ahead of the Release Zacks
Oct-25-18 12:42PM  How Does PTC Therapeutics Inc (NASDAQ:PTCT) Affect Your Portfolio Volatility? Simply Wall St. +5.28%
Oct-23-18 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
07:40AM  Market Trends Toward New Normal in PTC Therapeutics, AeroVironment, Autodesk, Coca-Cola Bottling Co. Consolidated, Akers Biosciences, and TEGNA Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Oct-22-18 04:30PM  PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2018 Financial Results PR Newswire
Oct-06-18 07:30AM  PTC Therapeutics Announces Initial Data from Patient Registry Demonstrating Translarna (ataluren) Slows Disease Progression in Children with Duchenne Caused by a Nonsense Mutation PR Newswire
Oct-03-18 07:30AM  Risdiplam Demonstrates Preliminary Evidence of Clinical Benefit in Type 1, 2, & 3 Spinal Muscular Atrophy Patients PR Newswire
Sep-28-18 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Sep-25-18 08:00AM  PTC Therapeutics to Participate at Upcoming Investor Conference PR Newswire
Sep-24-18 08:57AM  Do Options Traders Know Something About PTC Therapeutics (PTCT) Stock We Don't? Zacks
Sep-13-18 12:43PM  How Financially Strong Is PTC Therapeutics Inc (NASDAQ:PTCT)? Simply Wall St.
08:00AM  PTC Therapeutics to Participate at Upcoming Investor Conference PR Newswire
Sep-07-18 08:00AM  Today's Research Reports on Trending Tickers: bluebird bio and PTC Therapeutics ACCESSWIRE +6.25%
08:00AM  PTC Therapeutics Announces Winners of Global Duchenne Muscular Dystrophy Patient Group STRIVE Awards in Recognition of World Duchenne Awareness Day PR Newswire
Aug-28-18 08:10AM  New Research Coverage Highlights MACOM Technology Solutions, Arrowhead Pharmaceuticals, PTC Therapeutics, Boot Barn, Darling Ingredients, and Endologix Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Aug-24-18 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire -7.55%
Aug-23-18 04:30PM  PTC Therapeutics Successfully Completes Acquisition of Agilis Biotherapeutics PR Newswire
Aug-15-18 08:00AM  Today's Research Reports on Trending Tickers: Spark Therapeutics and PTC Therapeutics ACCESSWIRE
Aug-10-18 04:30PM  PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and strategic collaboration agreement with Odylia Therapeutics Inc. to develop gene therapies in rare inherited retinal diseases. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Boulding Mark ElliottExec. VP and CLOJul 05Option Exercise15.1015,312231,27933,899Jul 09 04:54 PM
Boulding Mark ElliottExec. VP and CLOJul 05Sale44.7415,312685,09729,524Jul 09 04:54 PM
Boulding Mark ElliottExec. VP and CLOJul 01Option Exercise24.23104,0922,521,639100,373Jul 02 06:46 PM
Utter Christine MarieSVP, Finance & CAOJul 01Option Exercise20.8113,071271,96814,234Jul 02 09:40 PM
Utter Christine MarieSVP, Finance & CAOJul 01Sale45.1513,071590,1434,937Jul 02 09:40 PM
Boulding Mark ElliottExec. VP and CLOJul 01Sale45.00104,0924,684,14029,524Jul 02 06:46 PM
Utter Christine MarieSVP, Finance & CAOJun 28Option Exercise20.8198820,5575,640Jul 02 09:40 PM
Boulding Mark ElliottExec. VP and CLOJun 28Option Exercise11.3577,575880,72373,614Jul 02 06:46 PM
Boulding Mark ElliottExec. VP and CLOJun 28Sale45.0077,5753,490,87529,524Jul 02 06:46 PM
Utter Christine MarieSVP, Finance & CAOJun 28Sale45.0098844,4604,937Jul 02 09:40 PM
Souza MarcioChief Operating OfficerJun 03Sale40.385,490221,68658,664Jun 04 09:09 PM
Utter Christine MariePrincipal Financial OfficerMar 05Option Exercise12.5526,200328,85223,687Mar 07 09:31 PM
Utter Christine MariePrincipal Financial OfficerMar 05Sale34.9728,7091,003,8244,937Mar 07 09:31 PM
SCHMERTZLER MICHAELDirectorJan 25Buy30.2066,2251,999,9951,386,594Jan 29 04:15 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 07Sale34.751806,2555,649Jan 09 05:14 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 07Sale34.7547316,43717,396Jan 09 05:14 PM
Souza MarcioChief Operating OfficerJan 07Sale34.75832,8842,742Jan 09 05:12 PM
Utter Christine MariePrincipal Financial OfficerJan 07Sale34.7529710,3217,446Jan 09 05:11 PM
Peltz Stuart WalterChief Executive OfficerJan 07Sale34.7574825,99317,538Jan 09 05:09 PM
Peltz Stuart WalterChief Executive OfficerJan 07Sale34.751,76461,29924,882Jan 09 05:09 PM